project . 2016 - 2023 . On going

EHVA

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 681032 Call for proposal: H2020-PHC-2015-single-stage_RTD
  • Funded under: H2020 | RIA Overall Budget: 28,224,700 EURFunder Contribution: 22,188,500 EUR
  • Status: On going
  • Start Date
    01 Jan 2016
    End Date
    30 Jun 2023
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vacci...
Description
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vacci...
Any information missing or wrong?Report an Issue